Impact of evolocumab on periprocedural microvascular damage in patients undergoing percutaneous coronary intervention (PCI)

Trial Profile

Impact of evolocumab on periprocedural microvascular damage in patients undergoing percutaneous coronary intervention (PCI)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2018

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms EVOLUTION Trial
  • Most Recent Events

    • 03 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top